Fulcrum Therapeutics (FULC) Stock
Rare disease biotech developing gene medicines. Here's the price, business snapshot, and what's worth knowing about Fulcrum Therapeutics in October 2026.
Fulcrum Therapeutics is a clinical-stage biotechnology company developing small-molecule medicines that aim to modulate gene expression for genetically defined diseases. Its lead programme targets facioscapulohumeral muscular dystrophy (FSHD), a rare muscle-wasting condition; clinical trial readouts and regulatory milestones are the key near-term catalysts. With a market capitalisation of roughly $525 million, Fulcrum is pre-commercial and relies on R&D progress rather than product revenues. Investing in Fulcrum means backing a binary, catalyst-driven story: positive trial data could materially re-rate the shares, while setbacks can be swift and severe. The company’s science is specialised and the timeline for returns can be long, so the stock tends to be volatile. This summary is general educational information only and not personal investment advice. Biotech investing carries significant risk and may not be suitable for all investors; consider your risk tolerance and consult an authorised financial adviser before making decisions.
Fulcrum Therapeutics (FULC) Stock Forecast
Analyst price target, next 12 months
$11.17
+203.4% vs today's $3.68
Price range over the last 12 months
Close to its 12-month low
Analysts covering Fulcrum Therapeutics have a consensus 12-month target of $11.17, above the current price of $3.68.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend selling Fulcrum Therapeutics stock due to a low target price compared to its current value.
Financial Health
Fulcrum Therapeutics is showing strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Upcoming clinical readouts and regulatory milestones can create sharp share moves, though outcomes are binary and may increase volatility.
Mechanism Focus
Fulcrum’s approach targets gene-expression control in genetically defined conditions — scientifically promising but dependent on clinical validation.
Rare Disease Market
Treating rare disorders like FSHD can offer meaningful commercial opportunity if approved, yet patient populations and reimbursement dynamics are specialised.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
